Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate.

Salter Amber Samantha Lancia Gary R Cutter Robert J Fox Kathryn C FitzgeraldJason P MendozaJames B Lewin

Published in: International journal of MS care (2021)

Most US NARCOMS Registry participants treated up to 5 years with DMF remained free from 6-month confirmed disability progression and conversion to secondary progressive MS and had stable disability and employment status. These results support the long-term stability of disability and work-related outcomes with disease-modifying therapy.

Keyphrases

multiple sclerosis
white matter
stem cells
mental illness
type diabetes
metabolic syndrome
bone marrow
skeletal muscle